The potential of recombinant adeno‐associated (rAAV) and oncolytic vaccinia virus to selectively target PD‐1 and CTLA‐4‐based therapy to the tumour site shows promise in preclinical evaluations.80, 81. Here, CTLA4 is linked to neoplasm.